{"id":103369,"date":"2020-03-06T08:07:07","date_gmt":"2020-03-06T16:07:07","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2020\/03\/coronavirus-takeda-pursues-plasma-derived-treatment-alnylam-and-vir-eye-sirna-therapy"},"modified":"2020-03-06T08:07:07","modified_gmt":"2020-03-06T16:07:07","slug":"coronavirus-takeda-pursues-plasma-derived-treatment-alnylam-and-vir-eye-sirna-therapy","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2020\/03\/coronavirus-takeda-pursues-plasma-derived-treatment-alnylam-and-vir-eye-sirna-therapy","title":{"rendered":"Coronavirus: Takeda Pursues Plasma-Derived Treatment; Alnylam and Vir Eye siRNA Therapy"},"content":{"rendered":"<p style=\"padding-right: 20px\"><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/coronavirus-takeda-pursues-plasma-derived-treatment-alnylam-and-vir-eye-sirna-therapy2.jpg\"><\/a><\/p>\n<p>Takeda said it has begun development of TAK-888, an anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) designed to treat high-risk individuals with COVID-19.<\/p>\n<p>Takeda\u2019s H-IGs are plasma derived-therapies that have previously shown effectiveness in treating of severe acute viral respiratory infections. Such therapies are designed to concentrate pathogen-specific antibodies from plasma collected from recovered patients or vaccinated donors in the future. By transferring the antibodies to a new patient, Takeda reasons, a person\u2019s immune system can better respond to the infection and increase their chance of recovery.<\/p>\n<hr>\n<p>Two big-name biopharmas\u2014Takeda Pharmaceutical and Alnylam Pharmaceuticals\u2014have separately entered the scramble to develop new treatments for SARS-CoV-2 infection, the virus identified as the cause of the global COVID-19 outbreak. [NIH].<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Takeda said it has begun development of TAK-888, an anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) designed to treat high-risk individuals with COVID-19. Takeda\u2019s H-IGs are plasma derived-therapies that have previously shown effectiveness in treating of severe acute viral respiratory infections. Such therapies are designed to concentrate pathogen-specific antibodies from plasma collected from recovered patients or vaccinated [\u2026]<\/p>\n","protected":false},"author":534,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,20],"tags":[],"class_list":["post-103369","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-futurism"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/103369","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/534"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=103369"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/103369\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=103369"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=103369"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=103369"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}